Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Enliven Therapeutics, Inc. ( ELVN ) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 11:30 AM EDT Company Participants Richard Fair - CEO, President & Director Benjamin Hohl - CFO & Head of Corporate Development Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Morgan Stanley, Research Division Okay. Good morning, everyone. I'm Sean Laaman, Head of U.S. Mid-cap Biotech Equity Research at Morgan Stanley, and welcome to Morgan Stanley's Global Healthcare Conference. Before we commence to make you aware of some important disclosures, please see those disclosures at the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have Enliven Therapeutics with CEO, Rick Fair; and CFO, Ben Hohl. Welcome both of you. Richard Fair CEO, President & Director Thanks, Sean. Appreciate it. Thanks for having us. Question-and-Answer Session Sean Laaman Morgan Stanley, Research Division Awesome. I might as well jump straight in. So certainly, I've got a few questions here on, of course ELVN-001 clinical differentiation and the CML strategy. So what is the single most important reason you believe ELVN-001 can ultimately outperform Scemblix commercially rather than simply coexist alongside it? Richard Fair CEO, President & Director Yes. Thanks, Sean. And again, thanks for having us. We appreciate it. I think candidly, we are very well positioned in our first launch to be sequenced after Scemblix. Scemblix is going to be well established as the market leader in first and second-line CML when we launch with our second-line plus label. In the long run, competing with them in the front line will be about the totality of the profile. We know that treatment selection in the frontline is driven by different factors for different patients. For a